{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:52:02Z","timestamp":1790787122765,"version":"4.1.0"},"reference-count":69,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T00:00:00Z","timestamp":1543795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17J02826"],"award-info":[{"award-number":["17J02826"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neurochemistry"],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:label\/>\n                    <jats:p>\n                      Oxaliplatin is widely used as a key drug in the treatment of colorectal cancer. However, its administration is associated with the dose\u2010limiting adverse effect, peripheral neuropathy. Platinum accumulation in the dorsal root ganglion (\n                      <jats:styled-content style=\"fixed-case\">DRG<\/jats:styled-content>\n                      ) is the major mechanism responsible for oxaliplatin\u2010induced neuropathy. Some drug transporters have been identified as platinum complex transporters in kidney or tumor cells, but not yet in\n                      <jats:styled-content style=\"fixed-case\">DRG<\/jats:styled-content>\n                      . In the present study, we investigated oxaliplatin transporters and their contribution to peripheral neuropathy. We identified 12 platinum transporters expressed in\n                      <jats:styled-content style=\"fixed-case\">DRG<\/jats:styled-content>\n                      with real\u2010time\n                      <jats:styled-content style=\"fixed-case\">PCR<\/jats:styled-content>\n                      , and their transiently overexpressing cells were established. After exposure to oxaliplatin, the accumulation of platinum in these overexpressing cells was evaluated using a coupled plasma mass spectrometer. Octn1\/2\u2010 and Mate1\u2010expressing cells showed the intracellular accumulation of oxaliplatin. In an animal study, peripheral neuropathy developed after the administration of oxaliplatin (4\u00a0mg\/kg, intravenously, twice a week) to si\n                      <jats:styled-content style=\"fixed-case\">RNA<\/jats:styled-content>\n                      \u2010injected rats (0.5\u00a0nmol, intrathecally, once a week) was demonstrated with the von Frey test. The knockdown of Octn1 in\n                      <jats:styled-content style=\"fixed-case\">DRG<\/jats:styled-content>\n                      ameliorated peripheral neuropathy, and decreased platinum accumulation in\n                      <jats:styled-content style=\"fixed-case\">DRG<\/jats:styled-content>\n                      , whereas the knockdown of Octn2 did not. Mate1 si\n                      <jats:styled-content style=\"fixed-case\">RNA<\/jats:styled-content>\n                      \u2010injected rats developed more severe neuropathy than control rats. These results indicate that Octn1 and Mate1 are involved in platinum accumulation at\n                      <jats:styled-content style=\"fixed-case\">DRG<\/jats:styled-content>\n                      and oxaliplatin\u2010induced peripheral neuropathy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:label\/>\n                    <jats:p>\n                      <jats:boxed-text content-type=\"graphic\" position=\"anchor\">\n                        <jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" mimetype=\"image\/png\" position=\"anchor\" specific-use=\"enlarged-web-image\" xlink:href=\"graphic\/jnc14607-fig-0008-m.png\">\n                          <jats:alt-text>image<\/jats:alt-text>\n                        <\/jats:graphic>\n                      <\/jats:boxed-text>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jnc.14607","type":"journal-article","created":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T11:22:33Z","timestamp":1538997753000},"page":"373-385","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Identification of drug transporters contributing to oxaliplatin\u2010induced peripheral neuropathy"],"prefix":"10.1111","volume":"148","author":[{"given":"Shunsuke","family":"Fujita","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacokinetics Graduate School of Pharmaceutical Sciences Kyushu University Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Hirota","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacokinetics Graduate School of Pharmaceutical Sciences Kyushu University Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Sakiyama","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacokinetics Graduate School of Pharmaceutical Sciences Kyushu University Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misaki","family":"Baba","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacokinetics Graduate School of Pharmaceutical Sciences Kyushu University Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3543-2562","authenticated-orcid":false,"given":"Ichiro","family":"Ieiri","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacokinetics Graduate School of Pharmaceutical Sciences Kyushu University Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,12,3]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2008.01.003"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/FBP.0000000000000026"},{"key":"e_1_2_7_4_1","first-page":"263","article-title":"Oxaliplatin, an anticancer agent that affects both Na+ and K+ channels in frog peripheral myelinated axons","volume":"25","author":"Benoit E.","year":"2006","journal-title":"Gen. Physiol. Biophys."},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00569.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00300-8"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-013-1192-z"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12576-016-0505-9"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2013.05.032"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0523-07.2007"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1385\/MO:19:4:261"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e328337b867"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-016-2920-x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.139"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.35525"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2009.04.029"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI1130"},{"key":"e_1_2_7_18_1","first-page":"1205","article-title":"Clinical pharmacokinetics of oxaliplatin: a critical review","volume":"6","author":"Graham M. A.","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.5.795"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.3816\/CCC.2005.s.006"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2017.11.015"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00090.2006"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/1440-1681.12088"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-004-0953-4"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/1744-8069-4-10"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.111.181297"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuro.2008.09.005"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpain.2010.08.006"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-007-9254-z"},{"key":"e_1_2_7_30_1","first-page":"1312","article-title":"Copper\u2010transporting P\u2010type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance","volume":"60","author":"Komatsu M.","year":"2000","journal-title":"Can. Res."},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.6652"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-5-116"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-1017-6"},{"key":"e_1_2_7_34_1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.36253\/ijae-1126","article-title":"The fundamental role of morphology in experimental neurotoxicology: the example of chemotherapy\u2010induced peripheral neurotoxicity","volume":"117","author":"Marmiroli P.","year":"2012","journal-title":"Ital. J. Anat. Embryol."},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2013.12.229"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2007.08.022"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-08-0840"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2010.08.019"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2011.02.051"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2018.07.006"},{"key":"e_1_2_7_41_1","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0022-3565(24)35167-5","article-title":"Na(+)\u2010dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance","volume":"291","author":"Ohashi R.","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.59.2.358"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2008.07.014"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0506483102"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2006.01.001"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-6-266"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2004.09.007"},{"key":"e_1_2_7_48_1","first-page":"249","article-title":"Management of oxaliplatin\u2010induced peripheral neuropathy","volume":"1","author":"Saif M. W.","year":"2005","journal-title":"Ther. Clin. Risk Manag."},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2009.09.003"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.66.1.25"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.1999.1026"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1118058109"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.1543.3.12"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1305321110"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuro.2006.04.010"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3740"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(97)01441-5"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2007.04.010"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-006-9016-3"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00312.2006"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2012.02.082"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2009.12.006"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.6000\/1927-3037.2015.04.02.3"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.07.056"},{"key":"e_1_2_7_65_1","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0022-3565(24)38199-6","article-title":"Novel membrane transporter OCTN1\u00a0mediates multispecific, bidirectional, and pH\u2010dependent transport of organic cations","volume":"289","author":"Yabuuchi H.","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12990-015-0072-8"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.13355"},{"key":"e_1_2_7_68_1","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0022-3565(24)38127-3","article-title":"Decreased tissue distribution of L\u2010carnitine in juvenile visceral steatosis mice","volume":"289","author":"Yokogawa K.","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-0769"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.1186\/1744-8069-8-55"}],"container-title":["Journal of Neurochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjnc.14607","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jnc.14607","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jnc.14607","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/am-pdf\/10.1111%2Fjnc.14607","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jnc.14607","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T18:57:37Z","timestamp":1775242657000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jnc.14607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,3]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.1111\/jnc.14607"],"URL":"https:\/\/doi.org\/10.1111\/jnc.14607","archive":["Portico"],"relation":{},"ISSN":["0022-3042","1471-4159"],"issn-type":[{"value":"0022-3042","type":"print"},{"value":"1471-4159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,3]]},"assertion":[{"value":"2018-02-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}